These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 19700404)

  • 21. On the role of Ca(2+)- and voltage-dependent inactivation in Ca(v)1.2 sensitivity for the phenylalkylamine (-)gallopamil.
    Sokolov S; Timin E; Hering S
    Circ Res; 2001 Oct; 89(8):700-8. PubMed ID: 11597993
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conserved Ca2+-antagonist-binding properties and putative folding structure of a recombinant high-affinity dihydropyridine-binding domain.
    Huber I; Wappl E; Herzog A; Mitterdorfer J; Glossmann H; Langer T; Striessnig J
    Biochem J; 2000 May; 347 Pt 3(Pt 3):829-36. PubMed ID: 10769189
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structural modeling and identification of imperatorin as novel L-type calcium channel blocker.
    Lu W; Zhang T; Li P; Wang F; Pan X; Wang C; Hu Z; Zhang J
    Med Chem; 2013 Nov; 9(7):993-8. PubMed ID: 23061602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extra- and intracellular action of quaternary devapamil on muscle L-type Ca(2+)-channels.
    Berjukov S; Aczel S; Beyer B; Kimball SD; Dichtl M; Hering S; Striessnig J
    Br J Pharmacol; 1996 Nov; 119(6):1197-202. PubMed ID: 8937723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular determinants of diltiazem block in domains IIIS6 and IVS6 of L-type Ca(2+) channels.
    Hockerman GH; Dilmac N; Scheuer T; Catterall WA
    Mol Pharmacol; 2000 Dec; 58(6):1264-70. PubMed ID: 11093762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of selective calcium channel blockers on ions' permeation through the human Cav1.2 ion channel: A computational study.
    Mosa FES; C S; Feng T; Barakat K
    J Mol Graph Model; 2021 Jan; 102():107776. PubMed ID: 33137694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Investigation of the phenylalkylamine binding site in hKv1.3 (H399T), a mutant with a reduced C-type inactivated state.
    Dreker T; Grissmer S
    Mol Pharmacol; 2005 Oct; 68(4):966-73. PubMed ID: 16000530
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinctions in the molecular determinants of charged and neutral dihydropyridine block of L-type calcium channels.
    Lacinová L; An RH; Xia J; Ito H; Klugbauer N; Triggle D; Hofmann F; Kass RS
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1472-9. PubMed ID: 10336541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel dihydropyridine with 3-aryl meta-hydroxyl substitution blocks L-type calcium channels in rat cardiomyocytes.
    Galvis-Pareja D; Zapata-Torres G; Hidalgo J; Ayala P; Pedrozo Z; Ibarra C; Diaz-Araya G; Hall AR; Vicencio JM; Nuñez-Vergara L; Lavandero S
    Toxicol Appl Pharmacol; 2014 Aug; 279(1):53-62. PubMed ID: 24844443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 1,4-Dihydropyridine scaffold in medicinal chemistry, the story so far and perspectives (part 1): action in ion channels and GPCRs.
    Ioan P; Carosati E; Micucci M; Cruciani G; Broccatelli F; Zhorov BS; Chiarini A; Budriesi R
    Curr Med Chem; 2011; 18(32):4901-22. PubMed ID: 22050742
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential sensitivities of CaV1.2 IIS5-S6 mutants to 1,4-dihydropyridine analogs.
    Hui K; Kwok TC; Kostelecki W; Leen J; Roy PJ; Feng ZP
    Eur J Pharmacol; 2009 Jan; 602(2-3):255-61. PubMed ID: 19068212
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Allosteric interactions required for high-affinity binding of dihydropyridine antagonists to Ca(V)1.1 Channels are modulated by calcium in the pore.
    Peterson BZ; Catterall WA
    Mol Pharmacol; 2006 Aug; 70(2):667-75. PubMed ID: 16675661
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of phenylalkylamines and benzothiazepines on Ca(v)1.3-mediated Ca2+ currents in neonatal mouse inner hair cells.
    Tarabova B; Lacinova L; Engel J
    Eur J Pharmacol; 2007 Nov; 573(1-3):39-48. PubMed ID: 17651721
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular determinants of frequency dependence and Ca2+ potentiation of verapamil block in the pore region of Cav1.2.
    Dilmac N; Hilliard N; Hockerman GH
    Mol Pharmacol; 2004 Nov; 66(5):1236-47. PubMed ID: 15286207
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular determinants of drug binding and action on L-type calcium channels.
    Hockerman GH; Peterson BZ; Johnson BD; Catterall WA
    Annu Rev Pharmacol Toxicol; 1997; 37():361-96. PubMed ID: 9131258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of binding sites for calcium channel antagonists.
    Nakayama H; Kuniyasu A
    Jpn Heart J; 1996 Sep; 37(5):643-50. PubMed ID: 8973377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Structural modeling of calcium binding in the selectivity filter of the L-type calcium channel.
    Cheng RC; Tikhonov DB; Zhorov BS
    Eur Biophys J; 2010 Apr; 39(5):839-53. PubMed ID: 20054687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Block of the lymphocyte K(+) channel mKv1.3 by the phenylalkylamine verapamil: kinetic aspects of block and disruption of accumulation of block by a single point mutation.
    Röbe RJ; Grissmer S
    Br J Pharmacol; 2000 Dec; 131(7):1275-84. PubMed ID: 11090098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacophoric features and Ca2+ ion holding capacity of verapamil.
    Awasthi A; Yadav A
    Bioorg Med Chem Lett; 2005 Dec; 15(24):5412-5. PubMed ID: 16213727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. (S)-emopamil, a novel calcium and serotonin antagonist for the treatment of cerebrovascular disorders. 1st communication: pharmacological profile.
    Hofmann HP; Raschack M; Unger L
    Arzneimittelforschung; 1989 Mar; 39(3):304-8. PubMed ID: 2757655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.